ea0081p170 | Pituitary and Neuroendocrinology | ECE2022
L. Samson Susan
, Nachtigall Lisa B.
, Fleseriu Maria
, Molitch Mark E.
, Giustina Andrea
, Haviv Asi
, Biermasz Nienke
, Kennedy Laurence
, Jensterle Mojca
, Manning Patrick
, Elenkova Atanaska
, Melmed Shlomo
, Strasburger Christian J.
Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous phase 3 studies, the safety of OOC was shown to be consistent with iSRLs, without dose-dependent adverse reactions. In the double-blind, placebo-controlled period (DPC) of the CHIASMA OPTIMAL trial (NCT03252353), patients were randomized to twi...